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Abstract
We have reported previously that dihydropyridine-type calcium-
channel antagonists (DTCCA) such as nifedipine decrease
plasma markers of oxidative stress damage in systemic sclerosis
(SSc). To clarify the cellular basis of these beneficial effects, we
investigated the effects in vivo and in vitro of nifedipine on
superoxide anion (O2
•-) production by peripheral blood
monocytes. We compared 10 healthy controls with 12 patients
with SSc, first after interruption of treatment with DTCCA and
second after 2 weeks of treatment with nifedipine (60 mg/day).
O2
•- production by monocytes stimulated with phorbol myristate
acetate (PMA) was quantified by the cytochrome c reduction
method. We also investigated the effects in vitro of DTCCA on
O2
•- production and protein phosphorylation in healthy
monocytes and on protein kinase C (PKC) activity using
recombinant PKC. After DTCCA had been washed out,
monocytes from patients with SSc produced more O2
•- than
those from controls. Nifedipine treatment considerably
decreased O2
•- production by PMA-stimulated monocytes.
Treatment of healthy monocytes with nifedipine in vitro inhibited
PMA-induced O2
•- production and protein phosphorylation in a
dose-dependent manner. Finally, nifedipine strongly inhibited
the activity of recombinant PKC in vitro. Thus, the oxidative
stress damage observed in SSc is consistent with O2
•-
overproduction by primed monocytes. This was decreased by
nifedipine treatment both in vivo and in vitro. This beneficial
property of nifedipine seems to be mediated by its cellular action
and by the inhibition of PKC activity. This supports the
hypothesis that this drug could be useful for the treatment of
diseases associated with oxidative stress.
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Introduction
Systemic sclerosis (SSc) is a connective tissue disease,
characterised by vascular involvement with generalised
microangiopathy culminating in systemic fibrosis. Several
lines of evidence suggest that the generation of oxygen free
radicals is of major importance in the pathogenesis of SSc
[1]. Frequent episodes of reperfusion injury generate oxy-
gen free radicals locally, but increased lipid peroxidation is
not related to Raynaud's phenomenon only [2] and the
inflammatory process might also generate oxidative stress
[1].
Histological studies of cutaneous SSc lesions have
revealed early mononuclear cell infiltration of perivascular
spaces around small vessels [3,4], and mononuclear cells
might affect vascular and tissue lesions by producing vari-
ous molecules [5]. Monocytes seem to have a key function
in several disorders (for example atherosclerosis) associ-
ated with free radical generation [6]. Monocytes from
patients with SSc produce greater amounts of superoxide
anion (O2
•-) than those from healthy subjects and patients
with primary Raynaud's phenomenon [7].
Dihydropyridine-type calcium-channel antagonists
(DTCCA) are an essential treatment in SSc because they
DTCCA = dihydropyridine-type calcium-channel antagonists; fMLP = formyl-Met-Leu-Phe; IC50 = concentration for 50% inhibition; PKC = protein 
kinase C; PMA = phorbol myristate acetate; SSc = systemic sclerosis.
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decrease vasospastic propensity. These drugs are sus-
pected to have anti-oxidant properties in other diseases
[8,9]. We reported previously that nifedipine and nica-
rdipine decrease circulating markers of oxidative stress
damage in patients with SSc [10,11]. The aim of the
present study was to investigate O2
•- production ex vivo by
monocytes from patients with SSc after a wash-out and
during nifedipine treatment. We also investigated the
effects of nifedipine in vitro on O2
•- release from human
monocytes, on protein phosphorylation with phorbol myr-
istate acetate (PMA) as stimulator and on protein kinase C
(PKC) activity.
Methods
Reagents, except when specified, were provided by Sigma
(St Louis, MO, USA).
Patients
Twelve non-smoking patients with SSc were included
(three men and nine women); their mean age was 56 (±10
SD) years and the mean disease duration was 8 ± 5 years.
Each of the patients had been hospitalised for systematic
follow-up of the disease. SSc was classified as limited
cutaneous or diffuse cutaneous according to the criteria of
LeRoy and colleagues [12]. The clinical features of their
disease were assessed as recommended [13]; results are
detailed in Table 1.
The initial evaluation included biological tests performed on
the morning of admission, after 1 hour of rest at room tem-
perature; patients stopped taking calcium-channel block-
ers 3 days before admission [10]. This wash-out period
was long enough for DTCCAs to have ceased to have an
effect because the half-lives of nifedipine and nicardipine
lie between 6 and 11 h and these drugs are converted into
inactive metabolites. Patients were also evaluated 2 weeks
later, when they were receiving stable treatment (including
20 mg of nifedipine three times a day). As before, this was
done in the morning, after 1 h of rest at room temperature.
All patients gave written informed consent. The control sub-
jects were 10 healthy non-smokers from the laboratory staff
(8 women and 2 men, mean age 48 ± 9 years).
Monocyte preparation
Blood samples (20 ml) were collected on EDTA. Whole
blood was diluted 1:2 in RPMI 1640 solution (Eurobio, Les
Ulis, France), layered on 15 ml of Ficoll-Hypaque (relative
density 1.077; Eurobio) and centrifuged at 150 g for 25
min at room temperature to separate mononuclear cells
from red blood cells and polymorphonuclear neutrophils.
Mononuclear cells collected at the interface were washed
twice in RPMI 1640 solution and separated into
lymphocytes and monocytes by gradient centrifugation
with 47% Percoll (Pharmacia, Uppsala, Sweden) at 150 g
for 25 min. The purity of the monocyte population (more
Table 1
Clinical and biological characteristics of patients with systemic sclerosis (SSc)
Characteristic Limited SSc (n = 6) Diffuse SSc (n = 6)
Raynaud's phenomenon, n 6 6
Current digital vascular ulceration, n 0 0
Lung fibrosis (computed tomography scan), n 2 4
Forced vital capacity <75%, n 0 4
DLCOc/haemoglobin <80%, n 3 3
Pulmonary hypertension (sPAP >40 mmHg), n 0 0
Positive for anti-topoisomerase I antibodies, n 0 4
Positive for anti-centromere antibodies, n 3 0
Creatinine, µmol/l (range) 73.4 ± 12.5a (56–81) 76.4 ± 13.5a (60–90)
ESR, mm/h 13.6 ± 11a 18.6 ± 15a
C-reactive protein concentration, mg/l 7.6 ± 6.1a 8.8 ± 7.4a
Low dose of prednisone (ongoing treatment), n (mean mg/day) 2 (7) 4 (7.5)
Angiotensin-converting enzyme inhibitors, n 0 3
D-Penicillamine, n 0 2
Omeprazole, n 6 6
aMean ± SD.
DLCOc, carbon monoxide diffusing capacity of the lung corrected for haemoglobin; ESR, erythrocyte sedimentation rate; sPAP, systolic 
pulmonary arterial pressure.
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than 90%) was assessed by May–Grunwald–Giemsa
staining. Cells were diluted in RPMI and used immediately.
O2
•- (respiratory burst) assay
O2
•- was quantified by the cytochrome c reduction assay at
550 nm [14] with a Uvikon® spectrophotometer equipped
with a thermostat-controlled cuvette holder and a magnetic
stirrer. In brief, 840 µl of monocytes (2 × 106 cells) were
incubated at 37°C with 80 µM cytochome c in 1 ml of PBS
with stirring before stimulation with 10 µl of PMA (100 nM).
Absorbance was read against a reference blank curve con-
taining PBS and cytochrome c at 5, 10 and 15 min. Results
are expressed in nmoles of O2
•- per 106 cells using 21.2
mM/cm as the extinction coefficient. For in vitro evaluation
of the effects of DTCCAs, control monocytes were preincu-
bated for 30 min with the desired concentration of drugs or
vehicle (dimethyl sulphoxide, 100 µM) before stimulation
with PMA.
The respiratory burst of control and nifedipine-treated
monocytes induced by formyl-Met-Leu-Phe (fMLP) was
measured by a sensitive fluorimetric assay for hydrogen
peroxide under standard conditions [15] using the Amplex
Red fluorescent probe (Molecular Probes, Eugene, OR,
USA). The increase in the fluorescent signal (excitation and
emission wavelengths of 530 and 590 nm respectively)
was monitored continuously after the stimulation of mono-
cytes with 1 µM fMLP. Results are expressed as the per-
centage of control values, representing the total hydrogen
peroxide production.
The scavenging effect of nifedipine was studied in an assay
system containing nifedipine at the desired concentration
with 0.15 mM hypoxanthine, 1.5 mM EDTA and 0.025 mM
cytochrome c. The reaction was started by adding 0.1 U/ml
xanthine oxidase. Absorbance was read at 550 nm.
Protein phosphorylation in monocytes and in a cell-free 
system
Phosphorylated proteins were detected by using the fluo-
rescent Pro-Q-Diamond dye (Molecular Probes), which can
directly detect phosphate groups attached to tyrosine, ser-
ine or threonine residues in gels. In brief, monocytes from
healthy donors were treated with or without nifedipine and
stimulated for 10 min with 100 nM PMA (which induces the
activation of PKC). Reactions were stopped with ice-cold
buffer and cell lysates were prepared by incubating mono-
cytes for 30 min in 0.5 ml of ice-cold extraction buffer (350
nM NaCl, 20 mM Hepes-KOH, pH 7.9, 1 mM EDTA, 0.1
mM EGTA, 20% glycerol, 1% Nonidet P40, 1 mM dithioth-
reitol, 0.5 mM phenylmethylsulphonyl fluoride, 20 mM ß-
glycerophosphate, 0.1 mM Na3VO4 and 1 µg/ml each of
aprotinin, pepstatin and leupeptin). Cells were then dis-
rupted by sonication (three times 5 s) and proteins were
delipidated and desalted before being subjected to SDS
gel electrophoresis. Protein phosphorylation was also stud-
ied after treatment of a cytosolic fraction of resting mono-
cytes with PMA for 10 min. Protein samples (150 µg of a 1
mg/ml protein sample) were treated in vitro with nifedipine
for 30 min before stimulation of PKC with a mixture of dia-
cylglycerol and calcium. This was done with the PKC
Biotrak® enzyme assay (Amersham Biosciences, Little
Chalfont, Buckinghamshire, UK) in accordance with the
manufacturer's instructions. Proteins (50 µg) were sepa-
rated by SDS gel electrophoresis. Proteins were fluores-
cently stained by fixing the gels overnight in 50% methanol
and 10% trichloracetic acid. The gels were washed with
deionised water for 10–20 min, stained with Pro-Q-Dia-
mond for 180 min and destained by three washes in 4%
acetonitrile in 50 mM sodium acetate, pH 4, for 2 hours.
Gels were scanned with a fluorimager, a Typhoon 9400
laser scanner (Amersham Biosciences), with excitation at
532 nm and a 580 nm band pass emission filter for Pro-Q-
diamond dye detection. Phosphorylated proteins were
quantified densitometrically with the Image Quant software.
Results represent the net phosphorylation induced by
PMA, expressed as percentages of the control PMA lane
(taken as 100%).
PKC assay
PKC assays were performed in vitro with a biologically
active full-length recombinant isoform (Calbiochem, EMB
Biosciences, San Diego, CA, USA) and a non-radioactive
PKC kinase assay kit (Stressgen, Victoria, BC, Canada).
The principle is based on an enzyme-linked immunosorbent
assay method that uses a specific synthetic peptide as a
substrate for PKC and a polyclonal antibody that recog-
nised the phosphorylated form of the substrate. In brief, 1
µl of recombinant PKC (5 µg/ml) in 30 µl of kinase assay
dilution buffer was incubated for 20 min at 37°C with the
drug vehicle (control) or with nifedipine or two other PKC
inhibitors (calphostin and GFI09203). PKC was then acti-
vated by 10 µl of PMA (100 nM) for 10 min at 37°C and the
reaction was blocked by incubating tubes in ice-cold water.
PKC activity was then determined as recommended by the
manufacturer. Results are expressed as percentages of the
net activity induced by PMA (taken as 100%).
Approval and consent
The study was approved by local ethics committee, and all
patients gave written informed consent.
Statistical analysis
Data were compared with the nonparametric Mann–Whit-
ney (unpaired data) and Wilcoxon (paired data) tests. P <
0.05 was considered significant. All quantitative data are
expressed as means ± SD.
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Results
Monocyte O2
•- production and respiratory burst
Monocytes from patients with SSc (n = 12) not treated by
nifedipine produced a significantly greater amount of O2
•-
than controls (n = 10) after stimulation ex vivo with the
PKC activator PMA for 15 min (9.1 ± 1.7 versus 5.4 ± 0.7
nmol per 106 cells; P < 0.01; Fig. 1a). This difference was
also observed when monocytes were stimulated with PMA
for 10 min (7.6 ± 2.3 versus 4.3 ± 0.8 nmol per 106 cells;
P < 0.01) but not when they were stimulated for 5 min (2.7
± 0.8 versus 2.1 ± 0.4 nmol per 106 cells; not significant).
These observations suggest that the biochemical modifica-
tions affecting monocytes from patients with SSc might not
affect the kinetics of NADPH oxidase but rather its late reg-
ulatory mechanisms.
Monocytes from patients treated with nifedipine (60 mg/
day) for 14 days produced a significantly smaller amount of
O2
•- than monocytes from untreated patients with SSc after
stimulation with PMA for 5 min (1.0 ± 0.7 versus 2.7 ± 0.8
nmol per 106 cells; P < 0.05), 10 min (1.6 ± 1.4 versus 7.6
± 2.3 nmol per 106 cells; P < 0.001) and 15 min (1.8 ± 1.0
versus 9.1 ± 1.7 nmol per 106 cells; P < 0.001; Fig. 1a).
Disease subsets, in particular the cutaneous subtype, did
not influence baseline O2
•- production by monocytes or the
decrease in O2
•- production with nifedipine treatment.
To determine whether monocytes were directly altered by
nifedipine, monocytes from healthy donors were treated in
vitro with nifedipine for 30 min before stimulation with PMA.
Nifedipine induced a concentration-dependent inhibition of
O2
•- production at concentrations of 10 and 50 µM (n = 5)
(Fig. 1b). PMA induction was inhibited by 50% (IC50) by
approximately 3–5 µM nifedipine. This inhibitory effect of
nifedipine was not due to any cytotoxic effect, as deter-
mined by the trypan blue exclusion test (cell death less than
5%). The effects of nifedipine were next studied on the
monocyte respiratory burst induced by an inflammatory
agonist such as fMLP. However, fMLP induced very weak
monocyte O2
•- production in standard conditions, so respi-
ratory burst was measured with a fluorimetric assay. Treat-
ment of monocytes for 30 min with 5 and 10 µM nifedipine
significantly inhibited hydrogen peroxide production by 55
± 7% and 90 ± 9%, respectively, relative to controls (n =
3).
Next we studied whether other calcium-channel blockers
alter the O2
•- production of healthy monocytes (n = 5) (Fig.
1c). A strong and similar inhibitory effect was observed
with nifedipine or nicardipine, but a less marked inhibitory
effect was observed with diltiazem. To investigate whether
the inhibitory effect of nifedipine was due to the scavenging
of free radicals, O2
•- was generated by the xanthine/xan-
thine oxidase system in the presence of various concentra-
tions of nifedipine. In these conditions, nifedipine did not
affect O2
•- generation, ruling out a scavenger effect (data
not shown).
Protein phosphorylation
The production of O2
•- by phagocytes is dependent on the
activation of PKC, a family of isoenzymes that phosphor-
ylate various proteins including some components of the
NADPH oxidase. Because PMA directly activates various
PKC isoforms, we studied the effect of nifedipine on PKC-
dependent protein phosphorylation in healthy monocytes.
Phosphorylated proteins were directly detected in polyacr-
ylamide gels by using Pro-Q-Diamond, a fluorescent dye
that binds to phosphate groups on proteins. In the absence
of PMA, nifedipine inhibited the basal phosphorylation of
various proteins in monocytes (Fig. 2a). In monocytes not
treated with nifedipine, stimulation with PMA markedly
increased the phosphorylation state of various proteins and
nifedipine strongly decreased the PMA-induced phosphor-
ylation of proteins. Densitometric analysis of 10 major
Figure 1
Superoxide anion production by monocytes after induction with phorbol myristate acetate (PMA; 100 nM) for 15 min
myristate acetate (PMA; 100 nM) for 15 min. From healthy controls (n = 
10), patients with systemic sclerosis (SSc) after disruption of calcium-
channel blocker treatment (n = 12) (baseline) and patients with SSc 
after 14 days of treatment with 60 mg/day nifedipine (NIF) (n = 12) (a), 
from healthy donors (n = 5) treated with or without various concentra-
tions of nifedipine for 30 min before stimulation with PMA (b) and from 
healthy donors treated with or without calcium-channel blockers (10 
µM) before stimulation with PMA (c). *P < 0.05; **P < 0.01 relative to 
controls.
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phosphorylated protein bands with molecular masses of
between 60 and 15 kDa showed that nifedipine inhibited
the net protein phosphorylation induced by PMA in a con-
centration-dependent manner. The inhibition of phosphor-
ylation was also investigated in this cell system under the
same conditions with the classical PKC inhibitor calphos-
tin; the inhibition of protein phosphorylation had a quite
similar profile (Fig. 2b) with closed results on densitometric
analysis.
The inhibitory effects of nifedipine were also demonstrated
in a cell-free system in which the activity of PKCs present
in the cytosolic fraction of resting monocytes was directly
stimulated in the presence of a mixture of calcium and dia-
cylglycerol. In these conditions, treatment of the cytosolic
fraction with nifedipine abolished PKC-dependent protein
phosphorylation (Fig. 2c).
PKC activity in vitro
To determine whether PKC is a direct target of nifedipine,
we investigated kinase activity in vitro with a biologically
active PKC recombinant that was pretreated with or with-
out various concentrations of nifedipine or with other clas-
sical PKC inhibitors such as calphostin or GF109203X
[16]. Nifedipine (1, 10 and 50 µM) dose-dependently inhib-
ited PKC activity with an inhibition reaching about 80%.
Similar inhibition was observed with calphostin and
GF109203X (n = 3; Fig. 3). These results strongly suggest
that nifedipine might directly inhibit PKC.
Discussion
In this report we show that, first, ex vivo monocytes from
patients with SSc not treated with calcium-channel block-
ers produce more O2
•- than control monocytes; second,
nifedipine (60 mg/day) strongly inhibits the ability of mono-
cytes to produce O2
•- ex vivo; and third, nifedipine inhibits
O2
•- production by healthy monocytes in vitro, a property
associated with the inhibition of PKC-dependent protein
phosphorylation and PKC activity.
Since the proposal that free radicals have a function in SSc
[17], several reports have provided evidence that free radi-
cals are involved in the pathogenesis of this complex dis-
ease [1,2,7,18]. Vasospasm and ischaemia–reperfusion
are known to generate free radicals, but other factors such
as the inflammatory process might also be involved [1]. It
has been suggested that resting and PMA-stimulated
monocytes produce more O2
•- than controls [7]. This is
Figure 2
Effects of nifedipine (NIF) on phorbol myristate acetate (PMA)-induced protein phosphorylation in monocytes as detected with the fluorescent probe ProQ-Diamon
ProQ-Diamond. (a, b) Representative gels of phosphorylated protein from homogenates of monocytes from healthy donors, treated with the indi-
cated concentrations of nifedipine (a, b) or calphostin (CAL) (b) for 30 min and then stimulated with 100 nM PMA for 10 min. Right panels show a 
representative densitometric analysis of 10 protein bands (molecular masses from 15 to 60 kDa) that were strongly phosphorylated in the presence 
of PMA. (c) Effects of nifedipine on the cytosolic fraction of control monocytes treated in vitro with the indicated concentrations of nifedipine for 30 
min before stimulation of protein kinase C with a mixture of calcium and diacylglycerol. Results are the net phosphorylation induced by PMA, 
expressed relative to the PMA lane (taken as 100%).
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consistent with our observation that circulating monocytes
from patients with SSc stimulated ex vivo by PMA release
about twice as much O2
•- as controls, which is similar to
previous findings [7]. This PMA-dependent increase in O2
•-
suggests that circulating monocytes are in a primed state,
which is consistent with their prior exposure to a substimu-
latory dose of agonists such as cytokines or immune com-
plexes [19]. These data show that free radicals are
overproduced in SSc and that this is due at least partly to
monocytes. The mechanism of monocyte activation
remains unknown. However, ischaemic insult does not
seem sufficient to explain this phenomenon, which is
associated with NADPH oxidase activation and might
involve cytokines [7].
The main finding of this study is that the treatment of
patients with SSc with nifedipine (60 mg/day) strongly
decreases the production of O2
•- by monocytes and leads
to the disappearance of the monocyte priming state. PMA
was chosen because it mimics the activation of NADPH
oxidase by PKC, a mechanism also induced by most of the
physiological activators of monocytes. Mononuclear cells
are thought to be important in SSc [3-5] and in oxidative
stress because they release various mediators leading to
tissue injury. Unlike monocytes, polymorphonuclear neu-
trophils do not seem to be activated in SSc [7]. The results
reported here are consistent with our previous data show-
ing that dihydropyridine-type calcium-channel blockers can
reduce plasma markers of oxidative stress [10]. Together
with data showing a concomitant improvement of endothe-
lial injury [11], these results suggest that calcium-channel
blockers, especially the dihydropyridine type, are not only of
major importance for the treatment of Raynaud's phenome-
non and vasospastic propensity [20,21] but should also be
regarded as essential drugs that limit monocyte activation
and oxidative stress.
Several reports have demonstrated the anti-oxidant proper-
ties of calcium-channel blockers. In hypertensive rats, dihy-
dropyridine calcium-channel blockers decrease lipoprotein
oxidation and prolong survival independently of modifica-
tions of blood pressure [22]. In hypertensive patients, treat-
ment with nifedipine decreases lipoperoxide and
isoprostane concentrations and increases the plasma anti-
oxidant capacity while increasing endothelium-dependent
vasodilation by restoring nitric oxide bioavailability [23]. At
the cellular level, nifedipine can prevent ischaemia-induced
endothelial permeability mediated primarily by the inhibition
of PKC-a [24]. A study with activated human and rabbit
neutrophils [25] and another study in vascular smooth mus-
cle cells [26] suggested that PKC can be inhibited by nica-
rdipine. Our results are consistent with these findings and
further emphasise the ability of nifedipine to inhibit PKC
activity in vitro, as shown by the strong decrease in PMA-
induced protein phosphorylation in monocytes and in a cell-
free system and the inhibition of a recombinant isoform of
PKC. Analysis of the protein phosphorylation pattern
showed that nifedipine also inhibits basal phosphorylation
of proteins, indicating that other protein kinases might be
altered. The molecular mechanism by which nifedipine
inhibits PKC cannot be derived from our results and will
require further experiments. However, nifedipine inhibits
both basal and PMA-induced protein phosphorylation as
well as PKC activity, which suggests that nifedipine might
interact with both the regulatory and catalytic domains of
PKC.
The inhibition of PKC-dependent protein phosphorylation
might be part of the molecular mechanism responsible for
the loss of the primed state of monocytes from patients
with SSc treated with nifedipine. This is emphasised by the
fact that IC50 values were above 3–5 µM nifedipine for
PMA-induced O2
•- production in vitro (Fig. 1b) and also for
PKC-dependent phosphorylation (Fig. 2a). However, this
hypothesis must be tested with monocytes from patients
with SSc.
Nifedipine (10 and 50 µM) significantly inhibited O2
•-
release by activated monocytes in vitro; this is consistent
with results previously obtained with human neutrophils
[25]. The IC50 for calcium channels antagonist activity of
nifedipine is close to 100 pM [27] and the clinical plasma
concentration of nifedipine is close to 0.2 µM [28]. We
used higher nifedipine concentrations for experiments in
vitro; however, nifedipine can accumulate in membrane-
bounded structures, resulting in higher localised
Figure 3
Nifedipine (NIF), like the classical protein kinase C (PKC) inhibitors cal-phostin (CAL) or GF109203X, inhibited the PKC activity of recom-binant PKC as evaluated by an enzym -lin d immunosorbent assay method n = 3)
phostin (CAL) or GF109203X, inhibited the PKC activity of recom-
binant PKC as evaluated by an enzyme-linked immunosorbent assay 
method (n = 3). Results are the net phosphorylation induced by phor-
bol myristate acetate (PMA), expressed relative to the PMA lane (taken 
as 100%).
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concentrations [29]. Thus, our data with nifedipine and
other calcium-channel blockers in vitro could explain the
results obtained with monocytes from patients with SSc
treated with nifedipine.
We found that diltiazem had a weaker effect on O2
•- pro-
duction by activated monocytes than other calcium-chan-
nel blockers evaluated; this was previously reported using
human neutrophils [30] and suggests that dihydropyridine-
type calcium-channel blockers are the strongest inhibitors
of O2
•- production.
Most of the classical properties of nifedipine are exerted
through the modulation of L-type voltage-gated calcium
channels on smooth muscle cells. Such channels are also
present on monocytes; we suspect that the molecular
mechanism highlighted is independent of these channels,
but this will require further investigations. Calcium channel-
independent properties have previously been reported and
because these are not represented in endothelial cells they
cannot account for these cellular effects [31]. It was sug-
gested that these drugs act as scavengers; however, our
data, together with those on human polymorphonuclear
neutrophils [24], do not support this hypothesis.
Conclusion
Monocytes from patients with SSc adopt a priming state
resulting in increased ex vivo PKC-dependent production
of O2
•- relative to healthy monocytes. Treatment of patients
with SSc or of healthy monocytes in vitro markedly
decreased the ability of monocytes to generate O2
•- . Bio-
chemical analysis of protein phosphorylation in monocytes
and cell-free systems suggested that nifedipine directly
inhibits PKC activity. These results demonstrate the poten-
tial anti-oxidant effects of this drug, which might have
important clinical implications for SSc and other oxidative
stress-associated diseases.
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